triple negative breast cancer

[Nature Genetics] By monitoring epigenomes, transcriptomes and lineages with single-cell resolution, scientists showed that the repressive histone mark trimethylation of histone H3 at lysine 27 (H3K27me3) regulated cell fate at the onset of chemotherapy.

[Proceedings of the National Academy of Sciences of the United States of America] Scientists identified a membrane receptor for progesterone/17-hydroxyprogesterone and delineated the mechanisms by which GPR126 participated in potential tumor progression in TNBC.

[ACS Applied Bio Materials] Scientists described the use of two chemical modifications, incorporating a neuropilin receptor agonist peptide and a hypoxia-responsive lipid for targeting and release of an encapsulated drug from bovine milk exosomes toTNBC cells.

[Cell Death Discovery] TGF-β from tumor-associated macrophages activated RAD18 in triple-negative breast cancer to enhance tumor stemness, forming a positive feedback loop. Inhibition of YAP or TGF-β broke this loop and suppressed cancer stemness and proliferation.

[Matrix Biology] Scientists reported that estrogen receptor (ER)-positive breast cancers had lower hyaluronan synthase 2 antisense RNA 1 (HAS2-AS1) expression compared to ER-negative tumors. Moreover, the survival of patients with ER-negative tumors was higher when the expression of HAS2-AS1 was elevated.

[Cell Reports] The authors showed that high feline sarcoma-related non-receptor tyrosine kinase (FER) levels were also associated with improved outcomes after adjuvant taxane-based combination chemotherapy in high-risk, HER2-negative patients.